Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN- NTRK2 Fusion
- PMID: 32913990
- PMCID: PMC7446438
- DOI: 10.1200/PO.18.00101
Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN- NTRK2 Fusion
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Lawrence W. WuNo relationship to discloseTara PavlockNo relationship to discloseAlison PattersonNo relationship to discloseAnne PostNo relationship to discloseCaitlyn AmbroseNo relationship to discloseVeena RajaramNo relationship to discloseDean C. PavlickEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineMatthew CookeEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine Travel, Accommodations, Expenses: Foundation MedicineVincent A. MillerEmployment: Foundation Medicine Leadership: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine Patents, Royalties, Other Intellectual Property: Periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer CenterLee A. AlbackerEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineSiraj M. AliEmployment: Foundation Medicine Leadership: Incyte Stock and Other Ownership Interests: Exelixis, Blueprint Medicines, Agios Pharmaceuticals, Genocea Biosciences Patents, Royalties, Other Intellectual Property: Patents through Foundation Medicine, patents through Seres Therapeutics on microbiome in non-neoplastic disease (I)Steven SmithConsulting or Advisory Role: Loxo OncologyMichael C. CoxEmployment: Bayer AG, Loxo Oncology, Merck, Amgen Stock and Other Ownership Interests: Loxo Oncology, Bayer AG, Merck, Amgen Patents, Royalties, Other Intellectual Property: US patent 62/318,041 issued to Loxo Oncology (Inst)Andrew MartinNo relationship to discloseSteve MegisonNo relationship to discloseTheodore W. LaetschConsulting or Advisory Role: Novartis, Loxo Oncology, Eli Lilly, Bayer AG Research Funding: Pfizer (Inst)
Figures
Similar articles
-
Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1.JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14. JCO Precis Oncol. 2020. PMID: 32133433 Free PMC article. No abstract available.
-
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11. Cancer. 2018. PMID: 30204247 Free PMC article. Clinical Trial.
-
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Lancet Oncol. 2018. PMID: 29606586 Free PMC article. Clinical Trial.
-
Larotrectinib for the treatment of TRK fusion solid tumors.Expert Rev Anticancer Ther. 2019 Jan;19(1):1-10. doi: 10.1080/14737140.2019.1538796. Epub 2018 Oct 24. Expert Rev Anticancer Ther. 2019. PMID: 30350734 Review.
-
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1. Target Oncol. 2018. PMID: 30276762 Review.
Cited by
-
Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort.Diagnostics (Basel). 2022 Mar 9;12(3):668. doi: 10.3390/diagnostics12030668. Diagnostics (Basel). 2022. PMID: 35328221 Free PMC article.
-
Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.Diagn Pathol. 2023 Oct 21;18(1):116. doi: 10.1186/s13000-023-01400-1. Diagn Pathol. 2023. PMID: 37865792 Free PMC article.
-
Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.JCO Precis Oncol. 2024 May;8:e2300713. doi: 10.1200/PO.23.00713. JCO Precis Oncol. 2024. PMID: 38810175 Free PMC article.
References
-
- Alaggio R, Coffin CM. The evolution of pediatric soft tissue sarcoma classification in the last 50 years. Pediatr Dev Pathol. 2015;18:481–494. - PubMed
-
- Jo VY, Fletcher CD. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 2014;46:95–104. - PubMed
-
- Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group study. J Clin Oncol. 2005;23:4031–4038. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous